The deployment of molecular biomarkers that are indicative of sensitivity to tumor-targeted or immune-targeted cancer therapies improves the outcome of individual patients and increases the chances of successful drug approval. However, for many lethal malignancies, the majority of clinical trials are conducted with patients who do not have biomarkers and hence they miss the target.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer
BMC Medicine Open Access 19 February 2024
-
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
npj Precision Oncology Open Access 11 April 2023
-
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity
Nature Genetics Open Access 16 March 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jardim, D. L. et al. J. Natl. Cancer Inst. 107, djv253 (2015).
Schwaederle, M. et al. J. Clin. Oncol. 33, 3817–3825 (2015).
Schwaederle, M. et al. JAMA Oncol. 2, 1452–1459 (2016).
Jardim, D. L., Groves, E. S., Breitfeld, P. P. & Kurzrock, R. Cancer Treat. Rev. 52, 12–21 (2017).
Blumenthal, G. M. et al. J. Clin. Oncol. 33, 1008–1014 (2015).
Herbst, R. S. et al. J. Clin. Oncol. 22, 785–794 (2004).
Goel, N. & Reddy, S. S. Surg. Oncol. Clin. N. Am. 26, 767–790 (2017).
Golan, T. et al. N. Engl. J. Med. 381, 317–327 (2019).
Hegi, M. E. et al. N. Engl. J. Med. 352, 997–1003 (2005).
Pond, G. R. et al. J. Clin. Oncol. 36, 225–225 (2018).
Adashek, J. J., Salgia, M. & Pal, S. K. Urol. Case Rep. 19, 60–62 (2018).
Long, G. V. et al. Lancet Oncol. 20, 1083–1097 (2019).
Okamura, R. et al. JCO Precis. Oncol. https://doi.org/10.1200/PO.18.00183 (2018).
Kato, S. et al. Nat. Commun. 11, 4965 (2020).
Adashek, J. J., Subbiah, V. & Kurzrock, R. Trends Cancer https://doi.org/10.1016/j.trecan.2020.08.009 (2020).
Palmer, A. C. & Sorger, P. K. Cell 171, 1678–1691.e1613 (2017).
Acknowledgements
Funded in part by the Joan and Irwin Jacobs Fund, and by the National Cancer Institute grant P30 CA023100 (R.K.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.K. consults for Foundation Medicine, has received a speaker’s fee from Roche, and has research grants from ACT Genomics, Sysmex, Konica Minolta and OmniSeq. R.K. has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Boehringer Ingelheim and Konica Minolta; has consultant and/or speaker fees from LOXO, X-Biotech, Actuate Therapeutics, Genentech, Pfizer, Roche and NeoMed; has an equity interest in IDbyDNA and Curematch; and is a board member of CureMatch and CureMetrix and co-founder of CureMatch.
Rights and permissions
About this article
Cite this article
Adashek, J.J., Goloubev, A., Kato, S. et al. Missing the target in cancer therapy. Nat Cancer 2, 369–371 (2021). https://doi.org/10.1038/s43018-021-00204-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-021-00204-w
This article is cited by
-
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer
BMC Medicine (2024)
-
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
npj Genomic Medicine (2023)
-
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
npj Precision Oncology (2023)
-
The coming decade in precision oncology: six riddles
Nature Reviews Cancer (2023)
-
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity
Nature Genetics (2023)